No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Vanda Pharma Analyst Ratings
Vanda Pharmaceuticals: Promising Pipeline Developments and Market Potential Drive Buy Rating
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment
Express News | Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for Vgt-1849a, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences